UPCC 19418: A Phase 1/2a Dose-Finding Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma

Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of the study involves treatment of an expansion cohort to confirm the tolerability of treatment at the recommended dose and evaluate evidence of treatment efficacy. All patients in the expansion cohort will be tested for genetic alterations in an effort to identify potential biomarkers for response to PT-112 treatment.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  myeloma
• Age: - 99 Years
• Gender: All